



January 4, 2017

BioCryst to Present at the J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](http://www.biocryst.com) (NASDAQ:BCRX) today announced that [executives from BioCryst](#) are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the 35th annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2017 at 1:30 p.m. Pacific Time.

BioCryst's conference presentation slides will be available for downloading from the BioCryst website events page at noon on Sunday, January 8th Pacific Time at the link below: <http://investor.shareholder.com/biocryst/events.cfm>. The live audio webcast and a replay of the presentation will also be available at the link above.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB[®] (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and is currently marketed in the U.S., Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910

 [Primary Logo](#)

Source: BioCryst Pharmaceuticals

News Provided by Acquire Media